Answers are grounded in this paper and cite their sources.
This review uncovers microRNAs' roles in autoimmune processes in type 1 diabetes, suggesting new therapeutic targets and delivery methods.
The clinical translation of these insights remains hindered by limited access to human tissues, inconsistent candidate validation, and lack of delivery systems capable of targeting pancreatic beta-cells. Bridging mechanistic understanding with advanced delivery systems may transform miRNAs both as biomarkers and active therapeutic agents, opening a path toward precision interventions in T1D.
No takes yet. Share an insight, caveat, or question.
Grieco et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: